This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Companion Animal Preventive Cancer Vaccine Development
The threat of cancer in companion animals still persists. In order to assist you in developing preventive vaccines to protect companion animals from the risk of cancer, BioVenic has established the platform for companion animal preventive cancer vaccine development. Whether it is the prevention of virus-induced tumors or non-infectious tumor prevention, we provide corresponding development services to address your specific needs.
Our Services
Veterinary Virus-Induced Cancer Vaccine Development
In companion animals, certain cancer diseases can be triggered by the infection of related viruses, such as feline leukemia virus. BioVenic has established various platforms for veterinary viral vaccine development, offering comprehensive services ranging from target discovery and antigen preparation to later-stage safety and efficacy assessments, additionally adjuvant development. You can choose according to your specific development needs.
| Platforms | Description | Relative Services |
|---|---|---|
| Inactivated Veterinary Vaccine | By injecting inactivated viral pathogens, the animal's immune system is stimulated to generate an immune response against tumor antigens, thereby enhancing the animal's resistance to specific pathogens. |
Virus Cultivation Virus Inactivation Adjuvant Development |
| Peptide Veterinary Vaccine | Prepared using specific peptide segments from protein molecules, these segments are antigens associated with cancer, capable of eliciting an immune response in the animal's immune system against cancer cells. |
Antigen Epitope Screening Peptide Synthesis Carrier Protein Conjugation Adjuvant Development |
| mRNA Veterinary Vaccine | Host cells autonomously synthesize antigen proteins by providing mRNA encoding specific tumor antigens, stimulating the animal's immune system to generate a response against cancer antigens. |
Antigen Discovery mRNA Preparation Delivery System Development |
Neo-Antigen Vaccine Development
The efficiency of normal RNA transcription and splicing correction mechanisms is relatively low in tumors, leading to increased production of abnormal peptides, including frameshift antigens (FSA). FSA is a highly immunogenic novel cancer antigen that can elicit T-cell and antibody responses, thereby driving effective anti-tumor immune reactions.
Fig.1 How RNA-based shift peptides are generated in tumor cells.1
BioVenic leverages this characteristic of tumors to develop neo-antigen vaccines for companion animal cancer prevention. Unlike autologous cancer vaccines, this new vaccine is based on mutations commonly found in various cancers occurring in animals. This vaccine is grounded in producing neo-antigens (errors) during RNA transcription and splicing processes, generating frameshift antigens that the animal immune system can recognize.
- Frameshift Peptide Array Platform
Here are the simple procedures shown for you to know how we professionals establish the frameshift peptide array platform to develop animal preventive cancer vaccines.
| 1. Sample Preparation | RNA or proteins are extracted from animal tumor samples to contain information about the shifted peptide. |
| 2. Sequence Analysis | RNA or protein data are analyzed using bioinformatics tools to identify potential frameshift peptide sequences. |
| 3. Array Design | Select appropriate shifted peptides for array design and synthesize each shifted peptide to be immobilized into appropriate vectors. |
| 4. Antigen-Antibody Interaction |
Cancer patient sera were incubated together with the shifted peptide arrays and then fluorescently labeled secondary antibodies were applied. The slides were scanned, and the anti-shift peptide response was converted to fluorescence intensity. |
Identical shifted peptide arrays are used to identify collections of neo-peptides that together provide a spectrum of blood antibody binding activity across most major cancers. BioVenic will utilize them to complete the development of neo-antigen vaccines to prevent cancer in companion animals based on your research concept.
Why Choose Us?
- One-stop shop for companion animal cancer preventive vaccine research and development.
- BioVenic provide you with veterinary cancer vaccine development services for single tumor antigen prophylaxis and multi-antigen prophylaxis.
- Multiple development platforms for animal cancer preventive vaccines R&D.
Some animal cancers may be transmitted through and caused by viruses. BioVenic offers services for preventive cancer vaccine development services, which can reduce the risk of cancer transmission. We have established a platform for neo-antigen vaccine development, enabling the stimulation of the animal's immune system to generate a stronger resistance against cancer cells. If you are interested in exploring this promising field, please feel free to contact us. We are dedicated to serving your needs!
Reference
- Shen, Luhui, et al. "RNA transcription and splicing errors as a source of cancer frameshift neoantigens for vaccines." Scientific reports 9.1 (2019): 14184.